TABLE 1.

Correlation of anti‐myeloma therapy and blood workup with serological response 1 month after second anti‐COVID‐19 vaccination

	Negative	Positive	Undetermined	p‐value
MM treatment	n = 36	n = 129	n = 11
Patients on active treatment	35 (97%)	91 (70.5%)	11 (100%)	<.001
Patients not on active treatment	1 (3%)	33 (28%)	0
Lines of therapy, mean ± SD	3.58 ± 2.00	1.58 ± 0.94	2.36 ± 2.06	^a <.001
Lines of therapy, mean ± SD				^b .034
s/p ASCT; yes	19 (53%)	83 (64%)	7 (64%)	.45
Specific anti‐MM therapy
Immunomodulators (n=82)	20 (57%)	55 (60%)	7 (64%)	.91
Proteasome inhibitors (n=63)	10 (29%)	46 (50.5%)	7 (64%)	.04
Anti‐CD38 immunotherapy (n=50)	19 (61%)	27 (30%)	4 (40%)	.007
Treatment with IVIg (n=23)	15 (41.7%)	7 (5.4%)	1 (9.1%)	<.0001
Blood workup (mean ± SD)	n = 33	n = 118	n = 10
Neutrophil count (×1000/μL), mean ± SD	3.58 ± 2.5	3.37 ± 1.7	3.79 ± 3.32	.97
Lymphocyte count (×1000/μL), mean ± SD	1.06 ± 0.71	1.5 ± 0.81	1.07 ± 0.46	^a <.001
Hemoglobin (g/dL), mean ± SD	11.078 ± 1.60	12.29 ± 1.64	11.73 ± 2.07	^a .001
Platelet count (×1000/μL), mean ± SD	165.97 ± 84.3	177.84 ± 67.2	117.36 ± 78.82	^b .018
Platelet count (×1000/μL), mean ± SD	165.97 ± 84.3	177.84 ± 67.2	117.36 ± 78.82	^c .001
Creatinine level (mg/dL), mean ± SD	1.42 ± 1.1	1.34 ± 1.64	1.08 ± 0.35	.38
Albumin level (g/dL), mean ± SD	3.85 ± 0.4	4.08 ± 0.34	3.89 ± 0.25	^a .002
Polyclonal IgG (mg/dL), mean ± SD	686.87 ± 1190	760.24 ± 448	561.46 ± 252	^a <.001
IgA (mg/dL), mean ± SD	125.24 ± 295	177.46 ± 458	76 ± 78	^a <.001
IgM (mg/dL), mean ± SD	14.21 ± 9	39.13 ± 39	38.76 ± 21	^a ^b <.001

Abbreviations: IgM, immunoglobulin M; IVIg, intravenous immunoglobulin; MM, multiple myeloma; s/p ASCT, status post autologous stem cell transplantation

Note: The values in bold type represent statistically significant findings.

^{^a}

Negative versus positive.

^{^b}

Negative versus undetermined.

^{^c}

Positive versus undetermined.